Latest Trials Latest NewsFAQ

Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-08-23

Last Posted Date: 2010-04-02

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00002674

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

First Posted Date: 2004-08-20

Last Posted Date: 2013-05-30

Lead Sponsor: Hackensack Meridian Health

Registration Number: NCT00004900

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

Liposomal Doxorubicin and Etoposide in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Peritoneal Cancer

Phase 1

Terminated

Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer
Fallopian Tube Cancer

First Posted Date: 2004-08-16

Last Posted Date: 2013-06-10

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00003380

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States

and more 60 locations

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer

Phase 2

Conditions: Lung Cancer

First Posted Date: 2004-08-13

Last Posted Date: 2014-01-06

Lead Sponsor: Herbert Irving Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT00003284

Locations: 🇺🇸
Herbert Irving Comprehensive Cancer Center, New York, New York, United States

High-Intensity, Brief-Duration Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2004-08-11

Last Posted Date: 2018-08-10

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 25

Registration Number: NCT00002865

Locations: 🇺🇸
Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2004-08-05

Last Posted Date: 2013-04-17

Lead Sponsor: Fox Chase Cancer Center

Target Recruit Count: 3

Registration Number: NCT00003957

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Combination Chemotherapy in Treating Patients With Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

First Posted Date: 2004-08-05

Last Posted Date: 2013-04-12

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 55

Registration Number: NCT00004186

Locations: 🇺🇸
University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States

S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

First Posted Date: 2004-08-02

Last Posted Date: 2012-07-24

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 96

Registration Number: NCT00003158

Locations: 🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
Providence Hospital - Southfield, Southfield, Michigan, United States
🇺🇸
CCOP - Columbus, Columbus, Ohio, United States

and more 83 locations

Cyclosporine and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Conditions: Leukemia

First Posted Date: 2004-07-29

Last Posted Date: 2013-12-19

Lead Sponsor: University Medical Center Groningen

Target Recruit Count: 25

Registration Number: NCT00002688

Locations: 🇳🇱
Academisch Medisch Centrum, Amsterdam, Netherlands
🇳🇱
Academisch Ziekenhuis Groningen, Groningen, Netherlands
🇳🇱
Academisch Ziekenhuis Maastricht, Maastricht, Netherlands

and more 9 locations

SWOG-9400 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Previously Untreated Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia
Neutropenia
Thrombocytopenia

First Posted Date: 2004-07-29

Last Posted Date: 2015-03-06

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 50

Registration Number: NCT00002665

Locations: 🇺🇸
CCOP - Dayton, Kettering, Ohio, United States
🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
🇺🇸
Cleveland Clinic Cancer Center, Cleveland, Ohio, United States

and more 80 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy